MannKind Licenses SemBioSys' Plant-Produced Insulin
MannKind Corporation (Valencia, CA) has purchased an option to license plant-produced recombinant human insulin from SemBioSys Genetics Inc. (Calgary, Canada) for use primarily in MannKind's ultra-rapid acting insulin, Afresa.
MannKind Corporation (Valencia, CA) has purchased an option to license plant-produced recombinant human insulin from SemBioSys Genetics Inc. (Calgary, Canada) for use primarily in MannKind’s ultra-rapid acting insulin, Afresa.
SemBioSys' plant-produced insulin is human insulin produced from genetically enhanced safflower. More information about the plant-produced insulin can be found on the BioPharm web site.
SemBioSys has demonstrated that its plant-produced insulin is physically, structurally, and functionally indistinguishable from pharmaceutical-grade human insulin through analytical testing and preclinical sub-chronic toxicology studies in rodents and primates. SemBioSys is currently conducting a Phase 1–2 clinical trial of its plant-produced insulin. The three-arm study of up to 30 healthy volunteers is designed to demonstrate the bioequivalence of safflower-produced insulin to two commercial insulin standards. Full results are expected to be available during the first half of 2009.
The option expires on March 31, 2009. Mannkind has completed Phase 3 trials of Afresa and expects to file a new drug application for Afresa early this year.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
